Novartis announced Thursday an exclusive strategic partnership with Arvinas to advance an oral protein degrader for prostate cancer, while also announcing the tender offer for its $2.9 billion acquisition of MorphoSys has commenced.
Vertex Pharmaceuticals on Wednesday scooped up clinical-stage immunotherapy company Alpine Immune Sciences for $4.9 billion in cash in the largest acquisition of 2024, targeting autoimmune and inflammatory diseases.
Amylyx Pharmaceuticals on Thursday released interim results from its ongoing Phase II HELIOS trial, showing that its lead asset AMX0035 (sodium phenylbutyrate and taurursodiol) improved pancreatic function and glycemic control in adult patients with the rare, inherited neurodegenerative disease Wolfram syndrome.
GLP-1 receptor agonists—a popular drug class that includes Novo Nordisk’s Ozempic (semaglutide) and Victoza (liraglutide)—do not appear to increase the risk of thyroid cancer, according to a new study published Wednesday in The BMJ.
Preliminary Phase I/II data demonstrated that Merck and Kelun-Biotech’s TROP2-directed antibody-drug conjugate SKB264 can elicit promising disease control and even potentially extend survival among heavily pretreated patients with gastric or gastroesophageal junction cancer, according to an abstract presentation Tuesday at the 2024 American Association for Cancer Research annual meeting.
Los Angeles-based startup TORL BioTherapeutics on Wednesday closed a $158 million oversubscribed Series B-2 funding round, which will go toward the advancement of its pipeline of novel antibody-drug conjugates for oncology.
The American Association for Cancer Research’s annual conference kicks off Friday as more than 20,000 attendees descend on San Diego. Analysts and researchers who spoke with BioSpace said they’re looking forward to early scientific data, and antibody-drug conjugates (ADCs) will be a key focus.
Moderna shares rose 8% in morning trade on Tuesday after the company’s individualized cancer vaccine developed with Merck showed positive response in an early-stage trial in patients with a type of head and neck cancer.
Two biotechs, Nvelop Therapeutics and Seaport Therapeutics, emerged from stealth Tuesday with $100 million in financing as they look to target the neuropsychiatric and gene editing spaces, respectively.
Novartis is to cut up to 680 jobs in its development organization, which helps bring its drugs to market, the Swiss pharmaceuticals company said on Tuesday.
